Finance Watch: Resilience Raises $625m, Bringing New Cash To $1.2bn
Series D Round Combined With Prior Unannounced $600m Series C
The biomanufacturing firm National Resilience has raised more than $2bn in venture capital and millions more in fees from government and industry contracts since 2020. Also, Code Biotherapeutics raised $75m in series A cash, Concert grossed $66.4m and Amarin is cutting US jobs.
You may also be interested in...
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
Amarin’s drug, which costs £144.21 for a 30-day supply, is to be made available on the National Health Service in England and Wales for reducing the risk of cardiovascular events after NICE reversed its previous rejection of the product.
A missed primary endpoint in new top-line results from a Japanese trial with the stem cell therapy for stroke MultiStem hits Athersys and Japanese partner hard, casting a shadow over ongoing studies.